CYP19A1 and breast carcinoma: Musculoskeletal toxicity is a significant source of morbidity, noncompliance, and treatment discontinuation in patients taking adjuvant aromatase inhibitor (AI) therapy for estrogen receptor (ER) positive breast cancer, which can ultimately impact survival outcomes1.